Rapamycin for longevity: what the human evidence actually shows
See more of CureMed in your Google results.
Rapamycin is a drug that reliably makes mice live longer, and some people now take it off-label for that reason. This guide covers what has and hasn't been shown in humans, the real risks of taking an immunosuppressant when you don't need one, and who should never consider it.
Rapamycin is the most reproducible lifespan-extending drug in mice, which is why it dominates longevity discourse — but the only 48-week randomised, placebo-controlled trial in healthy adults (PEARL, n=129) missed its primary endpoint entirely. It met its safety objective, meaning low-dose intermittent dosing appears tolerable over a year. That is a real finding. It is not evidence the drug slows human aging, and it is dispensed off-label, largely as a compounded product, by telehealth companies that profit from the prescription.
- PEARL — the only randomised placebo-controlled human trial — enrolled 129 healthy adults aged 50 to 85 on placebo, 5 mg or 10 mg weekly for 48 weeks; 114 finished and were analysed. Visceral adiposity, its primary endpoint, did not change (η² = 0.001, p = 0.942).
- Its positive secondary findings were sex-stratified, dose-stratified and partly self-reported — signals that need replication, not a demonstrated effect.
- The trial's sponsor, AgelessRx, is a telehealth company that sells rapamycin. That doesn't make the data wrong; it means it isn't independent.
- Rapamycin is FDA-approved as an immunosuppressant, for renal-transplant rejection prophylaxis. That mechanism is exactly what's being repurposed for longevity, and it carries real risk in someone who isn't a transplant patient.
- Compounded rapamycin — how most people taking it off-label actually get it — has different bioavailability from the approved generic, which is why a dedicated study (NCT06550271) exists just to characterise that gap.
Graded by CureMed against human clinical evidence, and reviewed by CureMed Labs.
Which prescription drugs are proven to extend lifespan? None yet
No prescription drug is proven to extend human lifespan. Rapamycin, a transplant drug, makes mice live longer, but its best human trial (PEARL) ran one year in 114 adults and missed its main goal. Metformin, a diabetes drug, has two record studies that disagree (2014 and 2022), and the TAME trial that could settle it still needs funding for about 3,000 older adults.
What rapamycin actually does, and why mice live longer on it
Rapamycin allosterically inhibits mTORC1, a protein complex that senses amino acids, glucose and growth signals and, when active, drives cell growth and protein synthesis. Suppress it, and cells shift toward autophagy — clearing damaged proteins and organelles — and away from the growth programmes that geroscience links to age-related decline.
Across essentially every mouse strain and dosing regimen tested, mTOR inhibition extends lifespan. That consistency is unusual in aging biology and is the reason rapamycin is treated as the field's best-validated target — but a mechanism that works reliably in a short-lived model organism is a hypothesis in humans, not a result, until a human trial with a clinical endpoint says otherwise.
Rapamycin and its analogues, what each is actually approved for
| Drug | Class | Approved for | Longevity use |
|---|---|---|---|
| Rapamycin (sirolimus) | mTORC1 inhibitor | Renal-transplant rejection prophylaxis, lymphangioleiomyomatosis | Off-label, largely compounded, dispensed by telehealth |
| Everolimus | Rapalog (better oral bioavailability) | Oncology, transplant, TSC-associated indications | Investigated for immune function in older adults; no aging endpoint used |
PEARL: the only randomised trial, and what it actually found
PEARL is the trial cited most often as proof rapamycin works in humans. It was a 48-week, decentralised, double-blind, placebo-controlled study of intermittent compounded rapamycin — 5 mg or 10 mg once weekly — in 129 healthy, normatively-aging adults.
PEARL at a glance
| Detail | Finding |
|---|---|
| Design | 48-week, randomised, double-blind, placebo-controlled, decentralised |
| N | 129 enrolled; 114 finished and were analysed (39 placebo, 40 on 5 mg, 35 on 10 mg weekly) |
| Primary endpoint | Visceral adiposity by DXA — no change (η² = 0.001, p = 0.942) |
| Safety objective | Met — comparable adverse events across groups over a year |
| Positive findings | Sex- and dose-stratified secondary outcomes, partly self-reported |
| Sponsor | AgelessRx — a telehealth company that sells rapamycin |
The rest of the human evidence base
- No trial has ever used a clinical aging outcome — disability, multimorbidity, mortality — as a primary endpoint for rapamycin in humans. Every trial to date uses a surrogate.
- RESTOR (NCT06658093, n=194, recruiting) is a dose-finding pharmacokinetic study — the groundwork that arguably should have preceded widespread off-label use, not followed it.
- A separate observational study (NCT06550271, n=67) exists specifically because compounded rapamycin's bioavailability differs from the FDA-approved generic — meaning people taking the compounded version don't reliably know their own exposure.
How people actually take it off-label
There is no approved longevity dose, because there is no approved longevity indication. What exists is a widely-repeated pattern borrowed from PEARL — the only human RCT — and from the intermittent-dosing hypothesis originally proposed to reduce the immunosuppressive risk of continuous dosing used in transplant patients.
What PEARL actually tested — not a recommendation
| Dose | Frequency | What it showed |
|---|---|---|
| 5 mg | Once weekly | No change in visceral adiposity vs placebo; tolerable over 48 weeks |
| 10 mg | Once weekly | No change in visceral adiposity vs placebo; tolerable over 48 weeks |
Rapamycin is an immunosuppressant — that's not incidental
Rapamycin's FDA approval is for preventing organ-transplant rejection by suppressing the immune response. That is the same mechanism being repurposed for longevity, and it does not become side-effect-free because the person taking it doesn't have a transplant. Every known risk below follows directly from deliberately dampening mTOR-driven immune and repair pathways in someone who has no medical need to.
Known risks, off-label longevity use
| Risk | Why it happens | What it means in practice |
|---|---|---|
| Immunosuppression | The approved mechanism — it's designed to suppress immune response | Reduced ability to fight infection; live vaccines are contraindicated |
| Impaired wound healing | mTORC1 drives the cell growth wound repair depends on | Relevant before any planned surgery or dental work |
| Hyperlipidaemia | Common, dose-related effect of mTOR inhibition | Needs monitoring, especially alongside existing cardiovascular risk |
| Mouth ulcers (stomatitis) | Common, dose-related | Usually the first sign someone notices; often prompts dose reduction |
| Glucose intolerance | mTOR inhibition affects insulin signalling | Relevant for anyone with pre-diabetes or a metabolic risk profile |
The honest bottom line
Ranked on: fit for a stated situation, given the current evidence — not a recommendation to start. The only human RCT missed its primary endpoint; everything below assumes that is understood going in.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | You're healthy with no aging-drug trial access | Wait, or discuss with a prescriber who knows your full history | — |
| 2 | You have any planned surgery, dental work, or active infection | Not now | — |
| 3 | You're already on other medications | Get your stack checked before anything else | — |
| 4 | You're a transplant patient already on prescribed sirolimus | This page isn't about you | — |
- 01
You're healthy with no aging-drug trial access
Wait, or discuss with a prescriber who knows your full historyThe mouse data is genuinely compelling; the human data isn't there yet. Starting an immunosuppressant on mouse evidence alone, outside a monitored trial, is accepting real risk for an unproven benefit.
- 02
You have any planned surgery, dental work, or active infection
Not nowImpaired wound healing and immunosuppression are established, mechanism-driven risks — not hypothetical ones — and they apply regardless of what the longevity data eventually shows.
- 03
You're already on other medications
Get your stack checked before anything elseRapamycin's interaction profile is substantial. This is the first question a pharmacist asks, and it should be the first question you ask before considering a compounded prescription from a telehealth form.
- 04
You're a transplant patient already on prescribed sirolimus
This page isn't about youYou're on it for an approved indication, under monitoring. The off-label longevity question addressed here doesn't apply to your situation.
Frequently asked questions
Which prescription drugs are proven to extend lifespan?
None. No prescription drug has been proven in a human trial to extend lifespan in healthy people, and no regulator has approved any drug for aging. The two best-known candidates both fall short. Rapamycin, a transplant drug, makes mice live longer (9% in males and 14% in females in the US National Institute on Aging's testing programme, Nature 2009), but its best human trial, PEARL, ran one year, analysed 114 adults and missed its main goal. Metformin, a diabetes drug, has never been tested for lifespan in a randomised trial of people without diabetes.
Can metformin or rapamycin meaningfully extend healthy lifespan?
Nobody knows yet, and the honest answer today is 'not shown'. For rapamycin, the only year-long placebo-controlled trial in healthy adults (PEARL, 2025) found no change in its main measure, belly fat. For metformin, a 2014 UK records study of 78,241 people with diabetes on metformin found they outlived matched people without diabetes — but a 2022 Danish registry study, which included twins, found the opposite: people with diabetes started on metformin died sooner than people without diabetes (rate ratio 1.52). The trial designed to settle it, TAME — about 3,000 adults aged 65 to 79, followed for six years — is still raising money and has not started.
Which longevity drugs have the strongest clinical evidence?
Rapamycin has the strongest animal evidence; no longevity drug has strong human evidence. In people, the clinical record is one 48-week rapamycin trial that missed its main goal (PEARL), two short trials of related drugs that improved flu-vaccine response and lowered infections in older adults, and conflicting record studies for metformin. None measured how long people lived.
How safe are common longevity drugs and compounds?
Both are prescription drugs with real side effects. Rapamycin weakens the immune system by design; known effects include mouth ulcers, slower wound healing, higher cholesterol and more infections, and nobody has tested weekly low doses in healthy people for longer than a year. Metformin has decades of safety data in diabetes: stomach upset is common, long-term use can lower vitamin B12, and a rare but serious acid build-up in the blood (lactic acidosis) can occur with poor kidney function. Neither should be bought online or taken without a prescriber.
Does rapamycin actually extend human lifespan?
It hasn't been shown to. PEARL, the only 48-week randomised placebo-controlled trial in healthy adults, enrolled 129 people (114 finished and were analysed) on placebo, 5 mg or 10 mg weekly and found no change in its primary endpoint of visceral adiposity (p = 0.942). It met its safety objective — low-dose intermittent rapamycin appears tolerable over a year — which is a real finding, but a different one from proving it slows aging. Its positive secondary results were sex- and dose-stratified and partly self-reported, and the trial's sponsor sells rapamycin.
Is rapamycin safe for longevity use?
PEARL found it tolerable over 48 weeks at 5–10 mg weekly in healthy adults, with adverse events comparable to placebo. That is not the same as safe with no caveats: rapamycin is an approved immunosuppressant, and it carries known risks — impaired wound healing, hyperlipidaemia, mouth ulcers, glucose intolerance, and reduced infection resistance — that apply to anyone taking it, trial data or not. It is also frequently taken as a compounded product with different bioavailability from the studied drug, which adds a dosing unknown on top of the drug's own risk profile.
What rapamycin dosage is used for longevity?
There is no approved longevity dose. The pattern most often cited comes from PEARL, the only human RCT: 5 mg or 10 mg once weekly. That is what was studied in that trial, not a recommendation — dosing should be set by a prescriber who knows your full medical history and current medications, not copied from a trial protocol.
Is rapamycin an immunosuppressant?
Yes — that is its FDA-approved mechanism, used to prevent rejection in organ-transplant patients. Longevity use repurposes that same immunosuppressive action in people who have no transplant and no medical need for it, which is why the infection risk, impaired wound healing and drug-interaction profile are genuine considerations rather than fine print.
How do I talk to a doctor about taking rapamycin for aging?
Bring the PEARL trial by name (NCT04488601) rather than a general request for 'the longevity drug' — it lets a clinician see exactly what has and hasn't been shown. Disclose every other medication and supplement you take, since rapamycin's interaction profile is substantial, and be upfront that you're asking about an off-label, unproven use of an immunosuppressant rather than an approved indication.
Keep reading
- Anti-aging pharmaceuticals: what has actually been tested
Where rapamycin sits alongside senolytics, metformin and GLP-1s, graded the same way.
- Mounjaro vs Ozempic: which works better, and what it costs you
The other major off-label longevity drug category, graded with the same standard.
- Free stack check
Screen rapamycin against everything else you take before you start.
More in Anti-aging pharma
- The AI-designed drug that made patients 'biologically younger': what the trial actually measured
An AI-designed drug lowered predicted biological age across six clocks. It was a secondary analysis of 42 lung-disease patients. Here's what that means.
- Is there a pill that can make you live to 150?
No pill has ever extended human lifespan in a trial. Here is what the compounds behind the 'live to 150' headlines actually proved, and in which species.
- What are the most effective antiaging prescription treatments available?
Tretinoin, botulinum toxin and statins rank on randomised evidence above rapamycin, metformin and senolytics, which lack trial evidence for anti-ageing use.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
Botulinum toxin has the largest measured effect on dynamic wrinkles in randomised trials, ahead of tretinoin for photoaging and fillers for static folds.
- What antiaging pharmaceuticals work best for skin rejuvenation?
Tretinoin ranks first for skin rejuvenation, improving texture, fine wrinkles, and pigmentation in decades of trials, ahead of hydroquinone and Botox.
- Which doctor-prescribed antiaging drugs are safest long term?
Statins and antihypertensives top the safety ranking with 30-plus years of data; growth hormone and testosterone 'optimisation' rank lowest, with real harm.